VRTX · News · 20260816N

Revenue Performance and Mix

VERTEX PHARMACEUTICALS INC / MA · 2026-08-16 · Importance 29 · Surprise 22 · No source text

Vertex Pharmaceuticals reported revenue growth of 12.5% year over year in its recently reported quarter. Revenue exceeded analyst expectations despite a $0.01-per-share earnings miss. The digest does not provide quarterly revenue dollars, segment results, or sequential revenue changes.

Key facts

• Vertex Pharmaceuticals' reported revenue increased by 12.5% year over year. source
• Vertex Pharmaceuticals recently reported quarterly earnings, missing analyst EPS estimates but exceeding revenue expectations. source
• Vertex Pharmaceuticals missed earnings estimates by $0.01 per share. source
• TFR Capital LLC acquired a new position of 5,074 shares in Vertex Pharmaceuticals valued at approximately $2.52 million during the second quarter. source
• Institutional investors collectively own 90.96% of Vertex Pharmaceuticals' outstanding stock.
• ABN AMRO Bank N.V. purchased 125,970 shares of Vertex Pharmaceuticals during the second quarter valued at approximately $62.52 million. source
• S&CO Inc. acquired 4,103 shares of Vertex Pharmaceuticals during the second quarter worth approximately $2.04 million. source

Impact estimates